1Heatherley SV, Mullings EL, Tidbury MA, et al. (2006) Caffeine consumption among a sample of UK adults. Appetite 47, 266.
2Fredholm BB, Battig K, Holmen J, et al. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51, 83–133.
3Hollingworth H (1912) The influence of caffeine on mental and motor efficiency. Arch Psychol 22, 1–166.
4Magkos F & Kavouras SA (2005) Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. Crit Rev Food Sci Nutr 45, 535–562.
5Daly J (1993) Mechanism of action of caffeine. In Caffeine, Coffee, and Health, pp. 97–150 [Garattini S, editor]. New York: Raven Press.
6Umemura T, Higashi Y, Soga J, et al. (2006) Acute administration of caffeine on vascular function in humans: as a balance of endothelium-dependent vasodilator and adenosine receptor antagonist. J Hypertens 24, 172.
7Quinlan PT, Lane J, Moore KL, et al. (2000) The acute physiological and mood effects of tea and coffee: the role of caffeine level. Pharmacol Biochem Behav 66, 19–28.
8Smit HJ & Rogers PJ (2000) Effects of low doses of caffeine on cognitive performance, mood and thirst in low and higher caffeine consumers. Psychopharmacology (Berl) 152, 167–173.
9Smith A, Sturgess W, Gallagher J, et al. (1999) Effects of a low dose of caffeine given in different drinks on mood and performance. Hum Psychopharmacol 14, 473–482.
10Durlach PJ, Edmunds R, Howard L, et al. (2002) A rapid effect of caffeinated beverages on two choice reaction time tasks. Nutr Neurosci 5, 433–442.
11Brice C & Smith A (2001) The effects of caffeine on simulated driving, subjective alertness and sustained attention. Hum Psychopharmacol 16, 523–531.
12Childs E & de Wit H (2006) Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) 185, 514–523.
13James JE (1994) Does caffeine enhance or merely restore degraded psychomotor performance? Neuropsychobiology 30, 124–125.
14Richardson NJ, Rogers PJ, Elliman NA, et al. (1995) Mood and performance effects of caffeine in relation to acute and chronic caffeine deprivation. Pharmacol Biochem Behav 52, 313–320.
15Rogers PJ, Martin J, Smith C, et al. (2003) Absence of reinforcing, mood and psychomotor performance effects of caffeine in habitual non-consumers of caffeine. Psychopharmacology (Berl) 167, 54–62.
16Addicott MA & Laurienti PJ (2009) A comparison of the effects of caffeine following abstinence and normal caffeine use. Psychopharmacology (Berl) 207, 423–431.
17Haskell CF, Kennedy DO, Wesnes KA, et al. (2005) Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl) 179, 813–825.
18Hewlett P & Smith A (2006) Acute effects of caffeine in volunteers with different patterns of regular consumption. Hum Psychopharmacol 21, 167–180.
19James JE & Rogers PJ (2005) Effects of caffeine on performance and mood, withdrawal reversal is the most plausible explanation. Psychopharmacology (Berl) 182, 1–8.
20Lee BL & Ong CN (2000) Comparative analysis of tea catechins and theaflavins by high performance liquid chromatography and capillary electrophoresis. J Chromatogr A 881, 439–447.
21Ferruzzi MG (2010) The influence of beverage composition on delivery of phenolic compounds from coffee and tea. Physiol Behav 100, 33–41.
22Cooper KA, Campos-Gimenez E, Alvarez DJ, et al. (2007) Rapid reversed phase ultra-performance liquid chromatography analysis of the major cocoa polyphenols and inter-relationships of their concentrations in chocolate. J Agric Food Chem 55, 2841–2847.
23Magna A, Salamao AA, Vila M, et al. (2003) Comparative study of two spectrophotometric reagents for catechol analysis in guarana seeds powder. J Braz Chem Soc 14, 129–132.
24Farah A, De Paulis T, Trugo LC, et al. (2005) Effect of roasting on the formation of chlorogenic acid lactones in coffee. J Agric Food Chem 53, 1505–1513.
25Spencer J (2010) Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain. Proc Nutr Soc 69, 244–260.
26Spencer JPE, Vafeiadou K, Williams RJ, et al. (2012) Neuroinflammation: modulation by flavonoids and mechanisms of action. Mol Aspects Med 33, 83–97.
27Williams RJ & Spencer JPE (2012) Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med. 52, 35–45.
28Weisburger JH (1996) Tea antioxidants and health. In Handbook of Antioxidants, pp. 469–486 [Cadenas E and Packer L, editors]. New York: Dekker.
29Arab L, Liu W, Elashoff D, et al. (2009) Green and black tea consumption and risk of stroke: a meta-analysis. Stroke 40, 1786–1792.
30Rezai-Zadeh K, Arendash GW, Hou H, et al. (2008) Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 1214, 177–187.
31Lee YK, Yuk DY, Lee JW, et al. (2009) ( − )-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency. Brain Res 1250, 164–174.
32Levites Y, Amit T, Youdim MBH, et al. (2002) Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol ( − )-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 277, 30574–30580.
33Kim SJ, Jeong HJ, Lee KM, et al. (2007) Epigallocatechin-3-gallate suppresses NF-κB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 18, 587–596.
34Mandel SA, Avramovich-Tirosh Y, Reznichenko L, et al. (2005) Multifunctional activities of green tea catechins in neuroprotection. Neurosignals 14, 46–60.
35Levites Y, Weinreb O, Maor G, et al. (2001) Green tea polyphenol ( − )-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78, 1073–1082.
36Katiyar SK, Afaq F, Perez A, et al. (2001) Green tea polyphenol ( − )-epigallocatechin-3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress. Carcinogenesis 22, 287–294.
37Chou FP, Chu YC, Hsu JD, et al. (2000) Specific induction of glutathione S-transferase GSTM2 subunit expression by epigallocatechin gallate in rat liver. Biochem Pharmacol 60, 643–650.
38Xu Y, Li S, Chen R, et al. (2010) Antidepressant-like effect of low molecular proanthocyanidin in mice: involvement of monoaminergic system. Pharmacol Biochem Behav 94, 447–453.
39Choi YB, Kim YI, Lee KS, et al. (2004) Protective effect of epigallocatechin gallate on brain damage after transient middle cerebral artery occlusion in rats. Brain Res 1019, 47–54.
40Haque AM, Hashimoto M, Katakura M, et al. (2006) Long-term administration of green tea catechins improves spatial cognition learning ability in rats. J Nutr 136, 1043–1047.
41Unno K, Takabayashi F, Yoshida H, et al. (2007) Daily consumption of green tea catechin delays memory regression in aged mice. Biogerontology 8, 89–95.
42Lin YL & Lin JK (1997) ( − )-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor B. Mol Pharmacol 52, 465–472.
43Chan MMY, Fong D, Ho CT, et al. (1997) Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. Biochem Pharmacol 54, 1281–1286.
44Stevens JF, Miranda CL, Wolthers KR, et al. (2002) Identification and in vitro biological activities of hop proanthocyanidins: inhibition of nNOS activity and scavenging of reactive nitrogen species. J Agric Food Chem 50, 3435–3443.
45Lorenz M, Wessler S, Follmann E, et al. (2004) A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem 279, 6190–6195.
46Lorenz M, Urban J, Engelhardt U, et al. (2009) Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved. Basic Res Cardiol 104, 100–110.
47Chen ZY, Law WI, Yao XQ, et al. (2000) Inhibitory effects of purified green tea epicatechins on contraction and proliferation of arterial smooth muscle cells. Acta Pharmacol Sin 21, 835–840.
48Alvarez E, Campos M, Justiniano H, et al. (2006) Study of the mechanisms involved in the vasorelaxation induced by ( − )-epigallocatechin-3-gallate in rat aorta. Br J Pharmacol 147, 269–280.
49Widlansky ME, Hamburg NM, Anter E, et al. (2007) Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 26, 95–102.
50Shenouda SM & Vita JA (2007) Effects of flavonoid-containing beverages and EGCG on endothelial function. J Am Coll Nutr 26, 366S–372S.
51Alexopoulos N, Vlachopoulos C, Aznaouridis K, et al. (2008) The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prev Rehabil 15, 300–305.
52Nagaya N, Yamamoto H, Uematsu M, et al. (2004) Green tea reverses endothelial dysfunction in healthy smokers. Heart 90, 1485–1486.
53Buijsse B, Feskens EJM, Kok FJ, et al. (2006) Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study. Arch Intern Med 166, 411–417.
54Buijsse B, Weikert C, Drogan D, et al. (2010) Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults. Eur Heart J 31, 1616–1623.
55Djousse L, Hopkins PN, North KE, et al. (2011) Chocolate consumption is inversely associated with prevalent coronary heart disease: The National Heart, Lung, and Blood Institute Family Heart Study. Clin Nutr 30, 182–187.
56Fraga CG, Actis-Goretta L, Ottaviani JI, et al. (2005) Regular consumption of a flavanol-rich chocolate can improve oxidant stress in young soccer players. Clin Dev Immunol 12, 11–17.
57Grassi D, Lippi C, Necozione S, et al. (2005) Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 81, 611–614.
58Berry NM, Davison K, Coates AM, et al. (2010) Impact of cocoa flavanol consumption on blood pressure responsiveness to exercise. Br J Nutr 103, 1480–1484.
59Faridi Z, Njike VY, Dutta S, et al. (2008) Acute dark chocolate and cocoa ingestion and endothelial function: a randomized controlled crossover trial. Am J Clin Nutr 88, 58–63.
60Grassi D, Desideri G, Necozione S, et al. (2008) Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr 138, 1671–1676.
61Taubert D, Berkels R, Roesen R, et al. (2003) Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. JAMA 290, 1029–1030.
62Heiss C, Jahn S, Taylor M, et al. (2010) Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. J Am Coll Cardiol 56, 218–224.
63Grassi D, Necozione S, Lippi C, et al. (2005) Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 46, 398–405.
64Monagas M, Khan N, Andres-Lacueva C, et al. (2009) Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. Am J Clin Nutr 90, 1144–1150.
65Davison K, Coates AM, Buckley JD, et al. (2008) Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects. Int J Obes 32, 1289–1296.
66Heiss C, Dejam A, Kleinbongard P, et al. (2003) Vascular effects of cocoa rich in flavan-3-ols. JAMA 290, 1030–1031.
67Mellor DD, Sathyapalan T, Kilpatrick ES, et al. (2010) High-cocoa polyphenol-rich chocolate improves HDL cholesterol in type 2 diabetes patients. Diabet Med 27, 1318–1321.
68Njike VY, Faridi Z, Shuval K, et al. (2011) Effects of sugar-sweetened and sugar-free cocoa on endothelial function in overweight adults. Int J Cardiol 149, 83–88.
69Balzer J, Rassaf T, Heiss C, et al. (2008) Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients: a double-masked, randomized, controlled trial. Circulation 51, 2141–2149.
70Engler MB, Engler MM, Chen CY, et al. (2004) Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr 23, 197–204.
71Taubert D, Roesen R, Lehmann C, et al. (2007) Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA 298, 49–60.
72Ried K, Sullivan T, Fakler P, et al. (2010) Does chocolate reduce blood pressure? A meta-analysis. BMC Med 8, 8–39.
73Desch S, Kobler D, Schmidt J, et al. (2010) Low v. higher-dose dark chocolate and blood pressure in cardiovascular high-risk patients. Am J Hypertens 23, 694–700.
74Heiss C, Kleinbongard P, Dejam A, et al. (2005) Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol 46, 1276–1283.
75Vlachopoulos C, Aznaouridis K, Alexopoulos N, et al. (2005) Effect of dark chocolate on arterial function in healthy individuals. Am J Hypertens 18, 785–791.
76Janszky I, Mukamal KJ, Ljung R, et al. (2009) Chocolate consumption and mortality following a first acute myocardial infarction: the Stockholm Heart Epidemiology Program. J Intern Med 266, 248–257.
77Mostofsky E, Levitan EB, Wolk A, et al. (2010) Chocolate intake and incidence of heart failure: a population-based prospective study of middle-aged and elderly women. Circ Heart Fail 3, 612–616.
78Lewis JR, Prince RL, Zhu K, et al. (2010) Habitual chocolate intake and vascular disease: a prospective study of clinical outcomes in older women. Arch Intern Med 170, 1857–1858.
79Larsson SC, Virtamo J, Wolk A, et al. (2011) Chocolate consumption and risk of stroke in women. J Am Coll Cardiol 58, 1828–1829.
80Buitrago-Lopez A, Sanderson J, Johnson L, et al. (2011) Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ 343, d4488.
81Shah ZA, Li RC, Ahmad AS, et al. (2010) The flavanol ( − )-epicatechin prevents stroke damage through the Nrf2/HO1 pathway. J Cereb Blood Flow Metab 30, 1951–1961.
82Chu YF, Brown PH, Lyle BJ, et al. (2009) Roasted coffees high in lipophilic antioxidants and chlorogenic acid lactones are more neuroprotective than green coffees. J Agric Food Chem 57, 9801–9808.
83Kwon SH, Lee HK, Kim JA, et al. (2010) Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. Eur J Pharmacol 649, 210–217.
84Nathan PJ, Lu K, Gray M, et al. (2006) The neuropharmacology of l-theanine(N-ethyl-l-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother 6, 21–30.
85Yokogoshi H, Kobayashi M, Mochizuki M, et al. (1998) Effect of theanine, R-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res 23, 667–673.
86Kimura R & Murata T (1971) Influence of alkylamides of glutamic acid and related compounds on the central nervous system. 1. Central depressant effect of theanine. Chem Pharm Bull (Tokyo) 19, 1257–1261.
87Yokogoshi H, Kato Y, Sagesaka YM, Takiharamatsuura T, et al. (1995) Reduction effect of theanine on blood-pressure and brain 5-hydroxyindoles in spontaneously hypertensive rats. Biosci Biotechnol Biochem 59, 615–618.
88Kakuda T, Nozawa A & Sugimoto A (2002) Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci Biotechnol Biochem 66, 2683–2686.
89Egashira N, Hayakawa K, Mishima K, et al. (2004) Neuroprotective effect of γ-glutamylethylamide (theanine) on cerebral infarction in mice. Neurosci Lett 363, 58–61.
90Kakuda T, Yanase H, Utsunomiya K, et al. (2000) Protective effect of γ-glutamylethylamide (theanine) on ischemic delayed neuronal death in gerbils. Neurosci Lett 289, 189–192.
91Jarvis MJ (1993) Does caffeine intake enhance absolute levels of cognitive performance. Psychopharmacology (Berl) 110, 45–52.
92Hameleers P, Van Boxtel MPJ, Hogervorst E, et al. (2000) Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum Psychopharmacol 15, 573–581.
93van Boxtel MPJ, Schmitt JAJ, Bosma H, et al. (2003) The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol Biochem Behav 75, 921–927.
94Ritchie K, Carriere I, de Mendonca A, et al. (2007) The neuroprotective effects of caffeine – a prospective population study (the Three City Study). Neurology 69, 536–545.
95Maia L & de Mendonca A (2002) Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 9, 377–382.
96Lindsay J, Laurin D, Verreault R, et al. (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156, 445–453.
97Eskelinen MH, Ngandu T, Tuomilehto J, et al. (2009) Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 16, 85–91.
98Johnson-Kozlow M, Kritz-Silverstein D, Barrett-Connor E, et al. (2002) Coffee consumption and cognitive function among older adults. Am J Epidemiol 156, 842–850.
99van Gelder BM, Buijsse B, Tijhuis M, et al. (2007) Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr 61, 226–232.
100Wu M-S, Lan T-H, Chen C-M, et al. (2011) Socio-demographic and health-related factors associated with cognitive impairment in the elderly in Taiwan. BMC Public Health 11, 22.
101Laitala VS, Kaprio J, Koskenvuo M, et al. (2009) Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr 90, 640–646.
102Corley J, Jia X, Kyle JAM, et al. (2010) Caffeine consumption and cognitive function at age 70: The Lothian Birth Cohort 1936 Study. Psychosom Med 72, 206–214.
103Shimbo M, Nakamura K, Shi HJ, et al. (2005) Green tea consumption in everyday life and mental health. Public Health Nutr 8, 1300–1306.
104Kuriyama S, Hozawa A, Ohmori K, et al. (2006) Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project. Am J Clin Nutr 83, 355–361.
105Ng TP, Feng L, Niti M, et al. (2008) Tea consumption and cognitive impairment and decline in older Chinese adults. Am J Clin Nutr 88, 224–231.
106Bryan J, Tuckey M, Einother SJL, et al. (2012) Relationships between tea and other beverage consumption to work performance and mood. Appetite 58, 339–346.
107Commenges D, Scotet V, Renaud S, et al. (2000) Intake of flavonoids and risk of dementia. Eur J Epidemiol 16, 357–363.
108Letenneur L, Proust-Lima C, Le Gouge A, et al. (2007) Flavonoid intake and cognitive decline over a 10-year period. Am J Epidemiol 165, 1364–1371.
109Nurk E, Refsum H, Drevon CA, et al. (2009) Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr 139, 120–127.
110Muley A, Muley P, Shah M, et al. (2012) Coffee to reduce risk of type 2 diabetes?: a systematic review. Curr Diabetes Rev 8, 162–168.
111Wu TY, Hankinson SE, Willett WC, et al. (2005) Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in US women. Diabetes Care 28, 1390–1396.
112Loopstra-Masters RC, Liese AD, Haffner SM, et al. (2011) Associations between the intake of caffeinated and decaffeinated coffee and measures of insulin sensitivity and beta cell function. Diabetologia 54, 320–328.
113Warburton DM (1995) Effects of caffeine on cognition and mood without caffeine abstinence. Psychopharmacology (Berl) 119, 66–70.
114Hasenfratz M & Battig K (1994) Acute dose–effect relationships of caffeine and mental performance, EEG, cardiovascular and subjective parameters. Psychopharmacology (Berl) 114, 281–287.
115Philip P, Taillard J, Moore N, et al. (2006) The effects of coffee and napping on nighttime highway driving: a randomized trial. Ann Intern Med 144, 785–791.
116Smith A, Brice C, Nash J, et al. (2003) Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function. J Psychopharmacol 17, 283–292.
117Hindmarch I, Rigney U, Stanley N, et al. (2000) A naturalistic investigation of the effects of day-long consumption of tea, coffee and water on alertness, sleep onset and sleep quality. Psychopharmacology (Berl) 149, 203–216.
118Andrews SE, Blumenthal TD, Flaten MA, et al. (1998) Effects of caffeine and caffeine-associated stimuli on the human startle eyeblink reflex. Pharmacol Biochem Behav 59, 39–44.
119Cropley V, Croft R, Silber B, et al. (2011) Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study. Psychopharmacology (Berl) 219, 737–749.
120Kim J, Lee S, Shim J, et al. (2012) Caffeinated coffee, decaffeinated coffee, and the phenolic phytochemical chlorogenic acid up-regulate NQO1 expression and prevent H2O2-induced apoptosis in primary cortical neurons. Neurochem Int 60, 466–474.
121Kim SS, Park RY, Jeon HJ, et al. (2005) Neuroprotective effects of 3,5-dicaffeoylquinic acid on hydrogen peroxide-induced cell death in SH-SY5Y cells. Phytother Res 19, 243–245.
122Nakajima Y, Shimazawa M, Mishima S, et al. (2007) Water extract of propolis and its main constituents, caffeoylquinic acid derivatives, exert neuroprotective effects via antioxidant actions. Life Sci 80, 370–377.
123Hwang YP & Jeong HG (2008) The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett 582, 2655–2662.
124Lee KJ & Jeong HG (2007) Protective effects of kahweol and cafestol against hydrogen peroxide-induced oxidative stress and DNA damage. Toxicol Lett 173, 80–87.
125Kim JY, Jung KS, Jeong HG, et al. (2004) Suppressive effects of the kahweol and cafestol on cyclooxygenase-2 expression in macrophages. FEBS Lett 569, 321–326.
126Kim JY, Jung KS, Lee KJ, et al. (2004) The coffee diterpene kahweol suppress the inducible nitric oxide synthase expression in macrophages. Cancer Lett 213, 147–154.
127Quinlan P, Lane J, Aspinall L, et al. (1997) Effects of hot tea, coffee and water ingestion on physiological responses and mood: the role of caffeine, water and beverage type. Psychopharmacology (Berl) 134, 164–173.
128Hindmarch I, Quinlan PT, Moore KL, et al. (1998) The effects of black tea and other beverages on aspects of cognition and psychomotor performance. Psychopharmacology (Berl) 139, 230–238.
129Scott D, Rycroft JA, Aspen J, et al. (2004) The effect of drinking tea at high altitude on hydration status and mood. Eur J Appl Physiol 91, 493–498.
130De Bruin EA, Rowson MJ, Van Buren L, et al. (2011) Black tea improves attention and self-reported alertness. Appetite 56, 235–240.
131Steptoe A, Gibson EL, Vounonvirta R, et al. (2007) The effects of tea on psychophysiological stress responsivity and post-stress recovery: a randomised double-blind trial. Psychopharmacology (Berl) 190, 81–89.
132Henry JP & Stephens-Larson P (1984) Reduction of chronic psychosocial hypertension in mice by decaffeinated tea. Hypertension 6, 437–444.
133Heese T, Jenkinson J, Love C, et al. (2009) Anxiolytic effects of l-theanine – a component of green tea – when combined with midazolam, in the male Sprague–Dawley rat. AANA J 77, 445–449.
134Kobayashi K, Nagato Y, Aoi N, et al. (1998) Effects of l-theanine on the release of alpha-brain waves in human volunteers. Nippon Nogeikagaku Kaishi 72, 153–157.
135Nobre AC, Rao A, Owen GN, et al. (2008) l-Theanine, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr 17, Suppl. 1, 167–168.
136Gomez-Ramirez M, Higgins BA, Rycroft JA, et al. (2007) The deployment of intersensory selective attention: a high-density electrical mapping study of the effects of theanine. Clin Neuropharmacol 30, 25–38.
137Gomez-Ramirez M, Kelly SP, Montesi JL, et al. (2009) The effects of l-theanine on alpha-band oscillatory brain activity during a visuo-spatial attention task. Brain Topogr 22, 44–51.
138Foxe JJ, Morie KP, Laud PJ, et al. (2012) Assessing the effects of caffeine and theanine on the maintenance of vigilance during a sustained attention task. Neuropsychopharmacolgy 62, 2320–2327.
139Kimura K, Ozeki M, Juneja LR, et al. (2007) l-Theanine reduces psychological and physiological stress responses. Biol Psychol 74, 39–45.
140Rogers PJ, Smith JE, Heatherley SV, et al. (2008) Time for tea, mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology (Berl) 195, 569–577.
141Lu K, Gray MA, Oliver C, et al. (2004) The acute effects of l-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol 19, 457–465.
142Haskell CF, Kennedy DO, Milne AL, et al. (2008) The effects of l-theanine, caffeine and their combination on cognition and mood. Biol Psychol 77, 113–122.
143Kelly SP, Gomez-Ramirez M, Montesi JL, et al. (2008) l-Theanine and caffeine in combination affect human cognition as evidenced by oscillatory alpha-band activity and attention task performance. J Nutr 138, 1572S–1577S.
144Owen GN, Parnell H, De Bruin EA, et al. (2008) The combined effects of l-theanine and caffeine on cognitive performance and mood. Nutr Neurosci 11, 193–198.
145Einother SJL, Martens VEG, Rycroft JA, et al. (2010) l-Theanine and caffeine improve task switching but not intersensory attention or subjective alertness. Appetite 54, 406–409.
146Giesbrecht T, Rycroft JA, Rowson MJ, et al. (2010) The combination of l-theanine and caffeine improves cognitive performance and increases subjective alertness. Nutr Neurosci 13, 283–290.
147Wightman EL, Haskell CF, Forster JS, et al. (2012) Epigallocatechin gallate (EGCG), cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation. Hum Psychopharmacol 27, 177–186.
148Scholey A, Downey LA, Ciorciari J, et al. (2012) Acute neurocognitive effects of epigallocatechin gallate (EGCG). Appetite 58, 767–770.
149Fisher NDL, Hughes M, Gerhard-Herman M, et al. (2003) Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 21, 2281–2286.
150Flammer AJ, Hermann F, Sudano I, et al. (2007) Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 116, 2376–2382.
151Crews WD Jr, Harrison DW & Wright JW (2008) A double-blind, placebo-controlled, randomized trial of the effects of dark chocolate and cocoa on variables associated with neuropsychological functioning and cardiovascular health: clinical findings from a sample of healthy, cognitively intact older adults. Am J Clin Nutr 87, 872–880.
152Field DT, Williams CM, Butler LT, et al. (2011) Consumption of cocoa flavanols results in an acute improvement in visual and cognitive functions. Physiol Behav 103, 255–260.
153Mumford G, Evans S, Kaminski B, et al. (1994) Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology (Berl) 115, 1–8.
154Smit HJ, Gaffan EA & Rogers PJ (2004) Methylxanthines are the psycho-pharmacologically active constituents of chocolate. Psychopharmacology (Berl) 176, 412–419.
155Mitchell ES, Slettenaar M, Van der Meer N, et al. (2011) Differential contributions of theobromine and caffeine on mood, psychomotor performance and blood pressure. Physiol Behav 104, 816–822.
156Sorond FA, Lipsitz LA, Hollenberg NK, et al. (2008) Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans. Neuropsychiatr Dis Treat 4, 433–440.
157Cameron OG, Modell JG, Hariharan M, et al. (1990) Caffeine and human cerebral blood-flow – a positron emission tomography study. Life Sci 47, 1141–1146.
158Lunt MJ, Ragab S, Birch AA, et al. (2004) Comparison of caffeine-induced changes in cerebral blood flow and middle cerebral artery blood velocity shows that caffeine reduces middle cerebral artery diameter. Physiol Meas 25, 467–474.
159Sigmon SC, Herning RI, Better W, et al. (2009) Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. Psychopharmacology (Berl) 204, 573–585.
160Kennedy DO & Haskell CF (2011) Cerebral blood flow and behavioural effects of caffeine in habitual and non-habitual consumers of caffeine: a near infrared spectroscopy study. Biol Psychol 86, 298–306.
161Field AS, Laurienti PJ, Yen YF, et al. (2003) Dietary caffeine consumption and withdrawal: confounding variables in quantitative cerebral perfusion studies? Radiology 227, 129–135.
162Francis ST, Head K, Morris PG, et al. (2006) The effect of flavanol-rich cocoa on the fMRI response to a cognitive task in healthy young people. J Cardiovasc Pharmacol 47, S215–S220.
163Scholey AB, French SJ, Morris PJ, et al. (2010) Consumption of cocoa flavanols results in acute improvements in mood and cognitive performance during sustained mental effort. J Psychopharmacol 24, 1505–1514.
164Camfield DA, Scholey A, Pipingas A, et al. (2012) Steady state visually evoked potential (SSVEP) topography changes associated with cocoa flavanol consumption. Physiol Behav 105, 948–957.
165Henman AR (1982) Guaraná (Paullinia-cupana var sorbilis): ecological and social perspectives on an economic plant of the central Amazon basin. J Ethnopharmacol 6, 311–338.
166Weckerle CS, Stutz MA & Baumann TW (2003) Purine alkaloids in Paullinia. Phytochemistry 64, 735–742.
167Espinola EB, Dias RF, Mattei R, et al. (1997) Pharmacological activity of Guarana (Paullinia cupana Mart) in laboratory animals. J Ethnopharmacol 55, 223–229.
168Carlson M & Thompson RD (1998) Liquid chromatographic determination of methylxanthines and catechins in herbal preparations containing guarana. J AOAC Int 81, 691–701.
169Mattei R, Dias RF, Espinola EB, et al. (1998) Guarana (Paullinia cupana): toxic behavioral effects in laboratory animals and antioxidant activity in vitro. J Ethnopharmacol 60, 111–116.
170Galduróz JC & Carlini EA (1994) Acute effects of the Paulinia cupana, ‘Guaraná’ on the cognition of normal volunteers. Sao Paulo Med J 112, 607–611.
171Galduróz JC & Carlini EA (1996) The effects of long-term administration of guarana on the cognition of normal, elderly volunteers. Sao Paulo Med J 114, 1073–1078.
172Haskell CF, Kennedy DO, Wesnes KA, et al. (2007) A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans. J Psychopharmacol 21, 65–70.
173Kennedy DO, Haskell CF, Wesnes KA, et al. (2004) Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: comparison and interaction with Panax ginseng. Pharmacol Biochem Behav 79, 401–411.
174Kennedy DO, Haskell CF, Robertson B, et al. (2008) Improved cognitive performance and mental fatigue following a multi-vitamin and mineral supplement with added guaraná (Paullinia cupana). Appetite 50, 506–513.
175Shen L, Song LG, Ma H, et al. (2012) Tea consumption and risk of stroke: a dose–response meta-analysis of prospective studies. J Zhejiang Univ Sci B 13, 652–662.
176Langer S, Marshall LJ, Day AJ, et al. (2011) Flavanols and methylxanthines in commercially available dark chocolate: a study of the correlation with nonfat cocoa solids. J Agric Food Chem 59, 8435–8441.